Correlation Between Serum Anti-Müllerian Hormone & Müllerian Ducts Anomalies in Infertility

A

Ahmed M.Kamel

Status

Completed

Conditions

Infertility

Treatments

Other: Anti Mullerian hormone level; Mullerian duct anomaly type

Study type

Observational

Funder types

Other

Identifiers

NCT02436538
13546

Details and patient eligibility

About

Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance, is a dimeric glycoprotein that belongs to the transforming growth factor-beta family. It is involved in the regression of the Müllerian ducts during male fetal development. In the female, AMH is solely produced by the granulosa cells of preantral and small antral follicles, and regulates ovarian activity and follicular steroidogenesis

Full description

Following approval of the internal review board of Egyptian IVF-ET center, a retrospective analysis will be undertaken where a detailed review of the patients files who underwent intracytoplasmic sperm injection (ICSI) trials starting January 2010 till January 2015 will be done. Patients with diagnosed mullerian anomalies will have their name , age ,duration of infertility, serum FSH, LH ,& AMH levels recorded. The method of diagnosis (HSG, 3D/ultrasonography, hysteroscopy, or laparoscopy) will also be documented.

Enrollment

226 patients

Sex

Female

Ages

20 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

women with diagnosed mullerian anomlies whether clinically or through imaging

Exclusion criteria

  • previous ovarian surgery
  • ovarian drilling
  • polycystic ovarian syndrome (PCOs).

Trial design

226 participants in 1 patient group

Mullerian duct anomalies
Description:
Anti Mullerian hormone level; Mullerian duct anomaly type
Treatment:
Other: Anti Mullerian hormone level; Mullerian duct anomaly type

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems